RaQualia Pharma Inc. (TYO:4579)
Japan · Delayed Price · Currency is JPY 550.00
-26.00 (-4.51%)
Sep 3, 2025, 3:30 PM JST
RaQualia Pharma Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 3,231 | 3,107 | 1,901 | 2,918 | 2,776 | 1,107 | Upgrade | |
Revenue Growth (YoY) | 40.60% | 63.44% | -34.85% | 5.12% | 150.77% | -34.96% | Upgrade |
Cost of Revenue | 787 | 625 | 245 | 231 | 321 | 138 | Upgrade |
Gross Profit | 2,444 | 2,482 | 1,656 | 2,687 | 2,455 | 969 | Upgrade |
Selling, General & Admin | 831 | 782 | 615 | 566 | 615 | 518 | Upgrade |
Research & Development | 1,653 | 1,703 | 1,372 | 1,248 | 1,127 | 932 | Upgrade |
Operating Expenses | 2,694 | 2,695 | 1,993 | 1,820 | 1,747 | 1,455 | Upgrade |
Operating Income | -250 | -213 | -337 | 867 | 708 | -486 | Upgrade |
Interest Expense | -56 | -42 | -7 | -6 | -1 | - | Upgrade |
Interest & Investment Income | 12 | 8 | 9 | 13 | 22 | 31 | Upgrade |
Currency Exchange Gain (Loss) | -140 | 38 | 52 | 43 | 145 | -75 | Upgrade |
Other Non Operating Income (Expenses) | -2 | -130 | 11 | -17 | -1 | 3 | Upgrade |
EBT Excluding Unusual Items | -436 | -339 | -272 | 900 | 873 | -527 | Upgrade |
Gain (Loss) on Sale of Investments | - | 4 | - | -35 | 16 | 2 | Upgrade |
Asset Writedown | 60 | -23 | -22 | 3 | -10 | -2 | Upgrade |
Other Unusual Items | - | - | - | -18 | - | - | Upgrade |
Pretax Income | -376 | -358 | -294 | 850 | 879 | -527 | Upgrade |
Income Tax Expense | 150 | 137 | 29 | 127 | 124 | 79 | Upgrade |
Net Income | -526 | -495 | -323 | 723 | 755 | -606 | Upgrade |
Net Income to Common | -526 | -495 | -323 | 723 | 755 | -606 | Upgrade |
Net Income Growth | - | - | - | -4.24% | - | - | Upgrade |
Shares Outstanding (Basic) | 22 | 22 | 22 | 21 | 21 | 21 | Upgrade |
Shares Outstanding (Diluted) | 22 | 22 | 22 | 21 | 21 | 21 | Upgrade |
Shares Change (YoY) | 3.04% | 0.16% | 2.97% | 0.05% | 0.10% | 1.62% | Upgrade |
EPS (Basic) | -23.61 | -22.87 | -14.95 | 34.48 | 36.03 | -28.93 | Upgrade |
EPS (Diluted) | -23.61 | -22.87 | -14.95 | 34.47 | 36.03 | -28.93 | Upgrade |
EPS Growth | - | - | - | -4.34% | - | - | Upgrade |
Free Cash Flow | -45 | 84 | -923 | 1,449 | 274 | -438 | Upgrade |
Free Cash Flow Per Share | -2.02 | 3.88 | -42.72 | 69.06 | 13.06 | -20.91 | Upgrade |
Gross Margin | 75.64% | 79.88% | 87.11% | 92.08% | 88.44% | 87.53% | Upgrade |
Operating Margin | -7.74% | -6.86% | -17.73% | 29.71% | 25.50% | -43.90% | Upgrade |
Profit Margin | -16.28% | -15.93% | -16.99% | 24.78% | 27.20% | -54.74% | Upgrade |
Free Cash Flow Margin | -1.39% | 2.70% | -48.55% | 49.66% | 9.87% | -39.57% | Upgrade |
EBITDA | 229 | 188 | -162 | 1,014 | 849 | -362 | Upgrade |
EBITDA Margin | 7.09% | 6.05% | -8.52% | 34.75% | 30.58% | -32.70% | Upgrade |
D&A For EBITDA | 479 | 401 | 175 | 147 | 141 | 124 | Upgrade |
EBIT | -250 | -213 | -337 | 867 | 708 | -486 | Upgrade |
EBIT Margin | -7.74% | -6.86% | -17.73% | 29.71% | 25.50% | -43.90% | Upgrade |
Effective Tax Rate | - | - | - | 14.94% | 14.11% | - | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.